Payment overview · 2025
General Payments
$524.42
29 reported records · 9 companies
Healthcare provider profile · identity verified
Curtiss Walter Combs, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · TEMECULA, CA · NPI 1710925409
Verified facts
What the public records show
CMS Open Payments records show Curtiss Walter Combs, M.D. received $524.42 in general payments during 2025 across 29 reported records.
Amgen Inc. accounted for 30.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 273 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $160.70 | 30.6% | 14 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $83.97 | 16.0% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $80.34 | 15.3% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $58.03 | 11.1% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $53.86 | 10.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.44 | 8.1% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.81 | 3.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.67 | 2.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13.60 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $524.42 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $104.66 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $104.66 | 11 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $83.97 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $80.34 | 3 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $58.03 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $56.04 | 3 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $53.86 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.87 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $16.81 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 273 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 99 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
68 | 22 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
273 | 91 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
99 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
54 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2618 | 889 |
| Losartan Potassium | Losartan Potassium | 1346 | 494 |
| Amlodipine Besylate | Amlodipine Besylate | 1193 | 397 |
| Levothyroxine Sodium | Levothyroxine Sodium | 892 | 285 |
| Metformin Hcl | Metformin Hcl | 765 | 277 |
| Lisinopril | Lisinopril | 692 | 242 |
| Montelukast Sodium | Montelukast Sodium | 602 | 198 |
| Tamsulosin Hcl | Tamsulosin Hcl | 510 | 171 |
| Hydrochlorothiazide | Hydrochlorothiazide | 389 | 131 |
| Omeprazole | Omeprazole | 374 | 133 |
| Metoprolol Succinate | Metoprolol Succinate | 341 | 119 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 326 | 108 |
| Metoprolol Tartrate | Metoprolol Tartrate | 316 | 115 |
| Furosemide | Furosemide | 278 | 94 |
| Eliquis | Apixaban | 273 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 261 | 102 |
| Simvastatin | Simvastatin | 253 | 76 |
| Carvedilol | Carvedilol | 251 | 83 |
| Clopidogrel | Clopidogrel Bisulfate | 245 | 87 |
| Sertraline Hcl | Sertraline Hcl | 245 | 92 |
| Gabapentin | Gabapentin | 237 | 87 |
| Trazodone Hcl | Trazodone Hcl | 236 | 95 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 232 | 87 |
| Fluticasone Propionate | Fluticasone Propionate | 226 | 100 |
| Allopurinol | Allopurinol | 222 | 70 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 207 | 72 |
| Escitalopram Oxalate | Escitalopram Oxalate | 188 | 77 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 185 | 77 |
| Potassium Chloride | Potassium Chloride | 172 | 65 |
| Synthroid | Levothyroxine Sodium | 167 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 166 | 57 |
| Famotidine | Famotidine | 165 | 58 |
| Benazepril Hcl | Benazepril Hcl | 164 | 56 |
| Atenolol | Atenolol | 154 | 46 |
| Finasteride | Finasteride | 148 | 47 |
| Jardiance | Empagliflozin | 148 | 46 |
| Ezetimibe | Ezetimibe | 145 | 54 |
| Hydralazine Hcl | Hydralazine Hcl | 144 | 51 |
| Glipizide | Glipizide | 133 | 54 |
| Lovastatin | Lovastatin | 120 | 42 |
| Alendronate Sodium | Alendronate Sodium | 111 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 102 | 34 |
| Ozempic | Semaglutide | 99 | 34 |
| Januvia | Sitagliptin Phosphate | 98 | 25 |
| Xarelto | Rivaroxaban | 98 | 34 |
| Spironolactone | Spironolactone | 95 | 31 |
| Valsartan | Valsartan | 72 | 21 |
| Farxiga | Dapagliflozin Propanediol | 68 | 22 |
| Chlorthalidone | Chlorthalidone | 67 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 67 | 44 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | 19 |
| Ibandronate Sodium | Ibandronate Sodium | 59 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 59 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | 20 |
| Tramadol Hcl | Tramadol Hcl | 56 | 25 |
| Bupropion Xl | Bupropion Hcl | 54 | 28 |
| Propranolol Hcl | Propranolol Hcl | 54 | 18 |
| Rybelsus | Semaglutide | 54 | 17 |
| Sildenafil Citrate | Sildenafil Citrate | 52 | 14 |
| Acyclovir | Acyclovir | 51 | 22 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 51 | 15 |
| Nifedipine Er | Nifedipine | 51 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 48 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 15 |
| Donepezil Hcl | Donepezil Hcl | 46 | 17 |
| Enalapril Maleate | Enalapril Maleate | 46 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 18 |
| Spiriva Respimat | Tiotropium Bromide | 46 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 45 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 39 | 15 |
| Metformin Hcl Er | Metformin Hcl | 39 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 39 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 36 |
| Humalog Kwikpen U-100 | Insulin Lispro | 38 | 14 |
| Irbesartan | Irbesartan | 38 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | 14 |
| Valacyclovir | Valacyclovir Hcl | 36 | suppressed |
| Baclofen | Baclofen | 34 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 34 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 34 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 28 |
| Klor-Con M20 | Potassium Chloride | 31 | suppressed |
| Ramipril | Ramipril | 30 | 12 |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 27 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 23 |
| Klor-Con 10 | Potassium Chloride | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 20 |
| Diltiazem Hcl | Diltiazem Hcl | 21 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Invokana | Canagliflozin | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Nystatin | Nystatin | 18 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Acarbose | Acarbose | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 14 |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $524.42 · 29 records | Amgen Inc. | BREZTRI, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, Korlym, OTEZLA, Ozempic, REPATHA, TEPEZZA, THINPREP 2000 PROCESSOR, WaveWriter Alpha Prime 16 | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error